1. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis
- Author
-
David J. Pasta, Stefanie J. Millar, Wayne J. Morgan, Donald R. VanDevanter, Jeffrey S. Wagener, and Michael W. Konstan
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Treatment response ,Adolescent ,Cystic Fibrosis ,Logistic regression ,Gastroenterology ,Cystic fibrosis ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Anti-Infective Agents ,Forced Expiratory Volume ,030225 pediatrics ,Internal medicine ,Regression toward the mean ,Humans ,Medicine ,Child ,Lung ,Lung function ,Pulmonary exacerbation ,business.industry ,Odds ratio ,Antimicrobial ,medicine.disease ,030228 respiratory system ,Pediatrics, Perinatology and Child Health ,Disease Progression ,Female ,business - Abstract
BACKGROUND In cystic fibrosis, observation of a lung function drop (as percent predicted forced expiratory volume in 1 s [FEV1 ]; ppFEV1 ) frequently precedes pulmonary exacerbation (PEx) diagnosis. Recovery of ppFEV1 to a previous "baseline" is commonly used to assess antimicrobial treatment response. However, not all diagnosed PEx are associated with a ppFEV1 drop, and it is unclear whether these are a different type of PEx from those associated with a ppFEV1 drop. METHODS We analyzed pre- and posttreatment ppFEV1 for PEx recorded in the Epidemiologic Study of Cystic Fibrosis from 2003 through 2005. Baseline, pretreatment, and follow-up ppFEV1 were the best recorded within 12-months pre-PEx, the lowest recorded -30 to +3 days of treatment, and the best recorded during 6-month follow-up, respectively. Logistic regression models for return of ppFEV1 to baseline during follow-up were developed separately for PEx with ≥10%
- Published
- 2019